Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.81 |
| ▸ | MAOA | P21397 | 12/20 | 0.81 |
| ▸ | RCOR1 | Q9UKL0 | 7/20 | 0.81 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.81 |
| ▸ | MAOB | P27338 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562230 | 1.00 | KDM1A (0.81) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL15944932 | 0.90 | KDM1A (1.00) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL15944927 | 0.90 | KDM1A (1.00) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL2561894 | 0.90 | KDM1A (1.00) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL18353842 | 0.90 | KDM1A (1.00) | KDM1AMAOARCOR1KDM1BMAOB | |
| Hydrochloric Acid SCHEMBL14673169 | 0.89 | KDM1A (1.00) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL17287957 | 0.87 | KDM1A (0.62) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL2562143 | 0.87 | KDM1A (0.80) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL30816623 | 0.87 | KDM1A (0.80) | KDM1AMAOARCOR1KDM1BMAOB | |
| SCHEMBL2577097 | 0.86 | KDM1A (0.67) | KDM1AMAOARCOR1KDM1BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2026-03-17 | — | — | US | disclosed |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK6, KDM1B, KDM6B | KDM1A 7/4885MAOA 1440/4885RCOR1 144/4885 |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK3, CDKN1A, CDKL3 | KDM1A 26/4885MAOA 3373/4885RCOR1 587/4885 |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | KDM1B, DOT1L, EZH2 | KDM1A 10/4885MAOA 2144/4885RCOR1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.